Dupixent is now cleared with allergy medication for patients aged 12 years and older with chronic spontaneous urticaria (CSU), a condition characterized by itchy rashes and swelling beneath the skin.

FDA approves Dupixent as the first new CSU treatment in over a decade. 2. Phase 3 trial shows significant symptom reduction ...

“Dupixent is the first new targeted treatment for chronic spontaneous urticaria, or CSU, in over ten years, with pivotal trials demonstrating its ability to help patients significantly reduce ...

The condition is linked to Type 2 inflammation, which Dupixent helps target by blocking certain immune signaling pathways. The injection is already approved for CSU in several other countries ...

FDA Approves Dupixent for Chronic Skin ConditionThe FDA has approved the popular drug Dupixent (generic name, dupilumab) for adults and kids 12 and up with chronic spontaneous urticaria (CSU), a ...

Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) announced that the U.S. Food and Drug Administration has approved Dupixent for the treatment of adults and adolescents aged 12 years and older ...

The U.S. Food and Drug Administration approved the use of Sanofi and Regeneron's blockbuster drug Dupixent for patients with a type of skin condition, the two companies said on Friday.

Dupixent is now cleared with allergy medication for patients aged 12 years and older with chronic spontaneous urticaria (CSU), a condition characterized by itchy rashes and swelling beneath the skin.